Stock DNTH DIANTHUS THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Business Segments Dianthus Therapeutics, Inc.

Equities

DNTH

US2528281080

Biotechnology & Medical Research

End-of-day quote Nasdaq
Other stock markets
 2024-09-06 		5-day change 1st Jan Change
26.62 USD -4.86% Intraday chart for Dianthus Therapeutics, Inc. -3.73% +155.96%
Aug. 09 Wedbush Adjusts Dianthus Therapeutics' PT to $36 From $38, Keeps Outperform Rating MT
Aug. 08 Dianthus Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 CI

Sales 2023 by Business Segment

See more © MarketScreener.com

Sales 2023 by Geography

See more © MarketScreener.com

Historical Breakdown of Revenue by Business Segments

Net Income: Breakdown by Business Segment

Breakdown by Business Segment
Fiscal Period: December202120222023

Biological Products

   

Biotechnology (Startups)

1.48M 6.42M 2.83M

Total Assets

9.45M 83.11M 179M

CAPEX

-33K -139K -110K

EBT

-13.11M -28.48M -43.56M

D&A

- 147K 355K

Operating Income

-13.09M -29.7M -48.17M

Net Income

-13.11M -28.48M -43.56M

Geographical Revenue Distribution History

Geographical breakdown of sales
Fiscal Period: December202120222023

United States

1.48M 6.42M 2.83M

Total Assets

9.45M 83.11M 179M

D&A

- 147K 355K

CAPEX

-33K -139K -110K

Net Income

-13.11M -28.48M -43.56M

EBT

-13.11M -28.48M -43.56M

Operating Income

-13.09M -29.7M -48.17M
  1. Stock Market
  2. Equities
  3. DNTH Stock
  4. Financials Dianthus Therapeutics, Inc.
  5. Business Segments
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW